169 related articles for article (PubMed ID: 32474619)
1. Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors.
Mulas O; Caocci G; Stagno F; Bonifacio M; Annunziata M; Luciano L; Orlandi EM; Abruzzese E; Sgherza N; Martino B; Albano F; Galimberti S; Pregno P; Bocchia M; Castagnetti F; Tiribelli M; Binotto G; Gozzini A; Capodanno I; Fozza C; Luzi D; Efficace F; Simula MP; Scaffidi L; De Gregorio F; Elena C; Trawinska MM; Cattaneo D; Attolico I; Baratè C; Pirillo F; Sicuranza A; Gugliotta G; Stella R; Scalzulli E; Iurlo A; Foà R; Breccia M; La Nasa G
Ann Hematol; 2020 Jul; 99(7):1525-1530. PubMed ID: 32474619
[TBL] [Abstract][Full Text] [Related]
2. Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention.
Caocci G; Mulas O; Bonifacio M; Abruzzese E; Galimberti S; Orlandi EM; Iurlo A; Annunziata M; Luciano L; Castagnetti F; Gozzini A; Stagno F; Binotto G; Pregno P; Albano F; Martino B; Fozza C; Scaffidi L; Trawinska MM; Baratè C; Elena C; Cattaneo D; Scalzulli E; La Nasa G; Foà R; Breccia M
Int J Cardiol; 2019 Aug; 288():124-127. PubMed ID: 31029498
[TBL] [Abstract][Full Text] [Related]
3. Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart.
Caocci G; Mulas O; Abruzzese E; Luciano L; Iurlo A; Attolico I; Castagnetti F; Galimberti S; Sgherza N; Bonifacio M; Annunziata M; Gozzini A; Orlandi EM; Stagno F; Binotto G; Pregno P; Fozza C; Trawinska MM; De Gregorio F; Cattaneo D; Albano F; Gugliotta G; Baratè C; Scaffidi L; Elena C; Pirillo F; Scalzulli E; La Nasa G; Foà R; Breccia M
Hematol Oncol; 2019 Aug; 37(3):296-302. PubMed ID: 30892724
[TBL] [Abstract][Full Text] [Related]
4. Effects of imatinib mesylate on renin-angiotensin system (RAS) activity during the clinical course of chronic myeloid leukaemia.
Sayitoglu M; Haznedaroğlu IC; Hatirnaz O; Erbilgin Y; Aksu S; Koca E; Adiguzel C; Bayik M; Akalin I; Gülbas Z; Akay M; Unal A; Kaynar L; Ovali E; Yilmaz M; Yenerel M; Dagdas S; Ozet G; Ar C; Aydin Y; Soysal T; Durgun B; Ozcebe O; Tukun A; Ilhan O; Ozbek U
J Int Med Res; 2009; 37(4):1018-28. PubMed ID: 19761684
[TBL] [Abstract][Full Text] [Related]
5. Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors.
Etienne G; Dulucq S; Huguet F; Schmitt A; Lascaux A; Hayette S; Fort MP; Sujobert P; Bijou F; Morisset S; Tavitian S; Bidet A; Turcq B; Robbesyn F; Chollet C; Belloc F; Durrieu F; Mahon FX; Nicolini FE
Cancer Med; 2019 Sep; 8(11):5173-5182. PubMed ID: 31350815
[TBL] [Abstract][Full Text] [Related]
6. Renin-angiotensin system inhibition is associated with reduced risk of left atrial appendage thrombosis formation in patients with atrial fibrillation.
Suo Y; Zhang Y; Wang Y; Yuan M; Kariyawasam S; Tse G; Liu T; Fu H; Li G
Cardiol J; 2018; 25(5):611-620. PubMed ID: 28980280
[TBL] [Abstract][Full Text] [Related]
7. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan.
Omboni S; Volpe M
Adv Ther; 2019 Feb; 36(2):278-297. PubMed ID: 30591990
[TBL] [Abstract][Full Text] [Related]
9. Impact of hypertension and renin-angiotensin system inhibitors in aortic stenosis.
Capoulade R; Clavel MA; Mathieu P; Côté N; Dumesnil JG; Arsenault M; Bédard E; Pibarot P
Eur J Clin Invest; 2013 Dec; 43(12):1262-72. PubMed ID: 24117162
[TBL] [Abstract][Full Text] [Related]
10. Primary prevention of myocardial infarction with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertensive patients with rheumatoid arthritis-A nationwide cohort study.
Lin TT; Wu CK; Liao MT; Yang YH; Chen PC; Yeih DF; Lin LY
PLoS One; 2017; 12(12):e0188720. PubMed ID: 29216228
[TBL] [Abstract][Full Text] [Related]
11. Renin-angiotensin system inhibitors and risk of fractures: a prospective cohort study and meta-analysis of published observational cohort studies.
Kunutsor SK; Blom AW; Whitehouse MR; Kehoe PG; Laukkanen JA
Eur J Epidemiol; 2017 Nov; 32(11):947-959. PubMed ID: 28752198
[TBL] [Abstract][Full Text] [Related]
12. Comparative Effectiveness of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in Individuals With Advanced CKD: A Nationwide Observational Cohort Study.
Fu EL; Clase CM; Evans M; Lindholm B; Rotmans JI; Dekker FW; van Diepen M; Carrero JJ
Am J Kidney Dis; 2021 May; 77(5):719-729.e1. PubMed ID: 33246024
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of angiotensin receptor blockers vs. angiotensin-converting enzyme inhibitors on cardiovascular outcomes in patients initiating peritoneal dialysis.
Shen JI; Saxena AB; Montez-Rath ME; Leng L; Chang TI; Winkelmayer WC
J Nephrol; 2017 Apr; 30(2):281-288. PubMed ID: 27485007
[TBL] [Abstract][Full Text] [Related]
14. Effect of dual compared to no or single renin-angiotensin system blockade on risk of renal replacement therapy or death in predialysis patients: PREPARE-2 study.
Voskamp PWM; Dekker FW; van Diepen M; Hoogeveen EK;
J Am Soc Hypertens; 2017 Oct; 11(10):635-643. PubMed ID: 28802945
[TBL] [Abstract][Full Text] [Related]
15. A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan.
Wu LS; Chang SH; Chang GJ; Liu JR; Chan YH; Lee HF; Wen MS; Chen WJ; Yeh YH; Kuo CT; See LC
Cardiovasc Diabetol; 2016 Apr; 15():56. PubMed ID: 27039185
[TBL] [Abstract][Full Text] [Related]
16. Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors.
Nakazato T; Iriyama N; Tokuhira M; Ishikawa M; Sato E; Takaku T; Sugimoto KJ; Fujita H; Fujioka I; Kimura Y; Aisa Y; Iwanaga E; Asou N; Kizaki M; Hatta Y; Komatsu N; Kawaguchi T
Med Oncol; 2018 May; 35(7):99. PubMed ID: 29846829
[TBL] [Abstract][Full Text] [Related]
17. Mortality and Pre-Hospitalization use of Renin-Angiotensin System Inhibitors in Hypertensive COVID-19 Patients.
Chen C; Wang F; Chen P; Jiang J; Cui G; Zhou N; Moroni F; Moslehi JJ; Ammirati E; Wang DW
J Am Heart Assoc; 2020 Nov; 9(21):e017736. PubMed ID: 32807002
[TBL] [Abstract][Full Text] [Related]
18. Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee.
Januzzi JL; Garasic JM; Kasner SE; McDonald V; Petrie MC; Seltzer J; Mauro M; Croce K; Berman E; Deininger M; Hochhaus A; Pinilla-Ibarz J; Nicolini F; Kim DW; DeAngelo DJ; Kantarjian H; Xu J; Hall T; Srivastava S; Naranjo D; Cortes J
J Hematol Oncol; 2022 Jan; 15(1):1. PubMed ID: 34991679
[TBL] [Abstract][Full Text] [Related]
19. Effects of renin-angiotensin system blockers on the risk and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with hypertension.
Lee J; Jo SJ; Cho Y; Lee JH; Oh IY; Park JJ; Cho YS; Choi DJ
Korean J Intern Med; 2021 Mar; 36(Suppl 1):S123-S131. PubMed ID: 32872731
[TBL] [Abstract][Full Text] [Related]
20. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
Hsu TW; Liu JS; Hung SC; Kuo KL; Chang YK; Chen YC; Hsu CC; Tarng DC
JAMA Intern Med; 2014 Mar; 174(3):347-54. PubMed ID: 24343093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
